ImmunoGen seeks conjugate bliss as T-DM1 anticipation builds
This article was originally published in Scrip
Executive Summary
After more than 30 years of research that has contributed to the development of its antibody-drug conjugates (ADCs), and with one high-profile oncology candidate on the brink of possible US FDA approval, ImmunoGen is advancing its first wholly-owned ADCs developed with the company's Targeted Antibody Payload (TAP) technology into mid-stage development.